Clinical Trials | December 09, 2025
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Angelini Ventures has already invested €125 million in 22 startups
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
GV20 received an upfront payment and is eligible for additional milestone payments
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
Subscribe To Our Newsletter & Stay Updated
